These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30349206)

  • 1. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine.
    Gilman M; Li L; Hudson K; Lumley T; Myers G; Corte C; Littlewood R
    Patient Prefer Adherence; 2018; 12():2123-2129. PubMed ID: 30349206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged-Release Buprenorphine Therapy in Opioid Use Disorder Can Address Stigma and Improve Patient Quality of Life.
    Somaini L; Vecchio S; Corte C; Coppola C; Mahony A; Pitts A; Cutuli M; Orso R; Littlewood R
    Cureus; 2021 Oct; 13(10):e18513. PubMed ID: 34754672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring patient experience and satisfaction with depot buprenorphine formulations: A mixed-methods study.
    Allen E; Samadian S; Altobelli G; Johnson J; Holmwood C
    Drug Alcohol Rev; 2023 May; 42(4):791-802. PubMed ID: 36788357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Acting Buprenorphine Formulations as a New Strategy for the Treatment of Opioid Use Disorder.
    Maremmani I; Dematteis M; Gorzelanczyk EJ; Mugelli A; Walcher S; Torrens M
    J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication Treatment of Opioid Use Disorder.
    Bell J; Strang J
    Biol Psychiatry; 2020 Jan; 87(1):82-88. PubMed ID: 31420089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder.
    Tompkins CNE; Neale J; Strang J
    J Subst Abuse Treat; 2019 Sep; 104():64-71. PubMed ID: 31370986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'I just thought that was the best thing for me to do at this point': Exploring patient experiences with depot buprenorphine and their motivations to discontinue.
    Clay S; Treloar C; Degenhardt L; Grebely J; Christmass M; Gough C; Hayllar J; McDonough M; Henderson C; Crawford S; Farrell M; Marshall A
    Int J Drug Policy; 2023 May; 115():104002. PubMed ID: 37003194
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus.
    Dematteis M; Auriacombe M; D'Agnone O; Somaini L; Szerman N; Littlewood R; Alam F; Alho H; Benyamina A; Bobes J; Daulouede JP; Leonardi C; Maremmani I; Torrens M; Walcher S; Soyka M
    Expert Opin Pharmacother; 2017 Dec; 18(18):1987-1999. PubMed ID: 29183228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged-release opioid agonist therapy: qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations.
    Neale J; Tompkins CNE; Strang J
    Harm Reduct J; 2019 Apr; 16(1):25. PubMed ID: 30943990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia.
    Barnett A; Savic M; Lintzeris N; Bathish R; Arunogiri S; Dunlop AJ; Haber P; Graham R; Hayes V; Lubman DI
    Drug Alcohol Depend; 2021 Oct; 227():108959. PubMed ID: 34450472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations when prescribing opioid agonist therapies for people living with HIV.
    Tarfa A; Lier AJ; Shenoi SV; Springer SA
    Expert Rev Clin Pharmacol; 2024 Jul; 17(7):549-564. PubMed ID: 38946101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in the delivery of buprenorphine for opioid dependence.
    Rosenthal RN; Goradia VV
    Drug Des Devel Ther; 2017; 11():2493-2505. PubMed ID: 28894357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in Opioid Agonist Treatment Practice in Germany during the COVID-19 Pandemic: What Have Physicians Done, and What Would They Like to Keep Doing?
    Lehmann K; Kuhn S; Schulte B; Verthein U
    Eur Addict Res; 2023; 29(5):323-332. PubMed ID: 37557092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flexible delivery of opioid agonist treatment during COVID-19 in Norway: qualitative and quantitative findings from an online survey of provider experiences.
    McDonald R; Bech AB; Clausen T
    BMC Health Serv Res; 2023 Sep; 23(1):965. PubMed ID: 37679751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.